Vanguard Group
PRAH

Vanguard Group’s PRA Health Sciences, Inc. PRAH Stock Holding History

Vanguard Group’s Portfolio PRAH Stock Details PRAH Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-1,775,342
Closed -$293M – 4596
2021
Q2 		$293M Sell
1,775,342
-4,194,199
-70% -$700M 0.01% 1365
2021
Q1 		$915M Sell
5,969,541
-739,600
-11% -$100M 0.02% 660
2020
Q4 		$842M Buy
6,709,141
+120,184
+2% +$13.4M 0.02% 642
2020
Q3 		$668M Sell
6,588,957
-248,523
-4% -$25.3M 0.02% 659
2020
Q2 		$665M Sell
6,837,480
-164,873
-2% -$15.3M 0.02% 636
2020
Q1 		$581M Buy
7,002,353
+144,138
+2% +$14.1M 0.02% 613
2019
Q4 		$762M Buy
6,858,215
+25,752
+0.4% +$2.65M 0.03% 641
2019
Q3 		$678M Buy
6,832,463
+460,968
+7% +$45.8M 0.03% 655
2019
Q2 		$632M Buy
6,371,495
+78,746
+1% +$7.52M 0.02% 691
2019
Q1 		$694M Buy
6,292,749
+180,312
+3% +$18.8M 0.03% 631
2018
Q4 		$562M Buy
6,112,437
+300,465
+5% +$30.4M 0.03% 657
2018
Q3 		$640M Buy
5,811,972
+658,191
+13% +$68.5M 0.03% 675
2018
Q2 		$481M Sell
5,153,781
-243,192
-5% -$20.9M 0.02% 802
2018
Q1 		$448M Sell
5,396,973
-16,064
-0.3% -$1.43M 0.02% 803
2017
Q4 		$493M Buy
5,413,037
+16,292
+0.3% +$1.36M 0.02% 761
2017
Q3 		$411M Buy
5,396,745
+839,951
+18% +$63.5M 0.02% 809
2017
Q2 		$342M Sell
4,556,794
-102,798
-2% -$7.13M 0.02% 896
2017
Q1 		$304M Buy
4,659,592
+170,812
+4% +$10.1M 0.02% 942
2016
Q4 		$247M Buy
4,488,780
+846,093
+23% +$46.4M 0.01% 1037
2016
Q3 		$206M Buy
3,642,687
+252,494
+7% +$12.4M 0.01% 1087
2016
Q2 		$142M Buy
3,390,193
+852,713
+34% +$39.3M 0.01% 1267
2016
Q1 		$109M Buy
2,537,480
+580,891
+30% +$24.5M 0.01% 1429
2015
Q4 		$88.6M Buy
1,956,589
+309,841
+19% +$13M 0.01% 1546
2015
Q3 		$63.9M Buy
1,646,748
+163,832
+11% +$6.56M ﹤0.01% 1735
2015
Q2 		$53.9M Buy
1,482,916
+157,943
+12% +$5M ﹤0.01% 1898
2015
Q1 		$38.2M Buy
1,324,973
+1,290,196
+3,710% +$36M ﹤0.01% 2033
2014
Q4 		$842K Buy
+34,777
New +$784K ﹤0.01% 3588

Other funds holding PRAH

BCI
Brinker Capital Investments Berwyn, Pennsylvania $11.7B AUM 21.33% 1-Year Est. Return

Vanguard Group's PRAH Position: Q3 2021 in Review

Vanguard Group sold out of PRA Health Sciences, Inc. (PRAH) in Q3 2021, closing a stake of 1,775,342 shares — an estimated $293M sold.

Vanguard Group first reported a position in PRAH in Q4 2014 and held it in 27 quarters. The position peaked at $915M in Q1 2021. 1 fund tracked by Wall St. Rank holds PRAH as of Q3 2021.

  • Vanguard Group reported no remaining PRA Health Sciences, Inc. position as of Q3 2021 after selling out during the quarter.
  • Vanguard Group sold 1,775,342 PRA Health Sciences, Inc. shares in Q3 2021, an estimated $293M.
  • Vanguard Group first reported a position in PRA Health Sciences, Inc. in Q4 2014 and held it in 27 quarters.
  • Vanguard Group's PRA Health Sciences, Inc. position peaked at $915M in Q1 2021.
  • 1 fund tracked by Wall St. Rank held PRA Health Sciences, Inc. as of Q3 2021.

Based on Vanguard Group's 13F filing for Q3 2021, filed 12 Nov 2021.